Trade-Ideas LLC identified

Integra Lifesciences Holdings

(

IART

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Integra Lifesciences Holdings as such a stock due to the following factors:

  • IART has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $27.3 million.
  • IART has traded 3,135 shares today.
  • IART is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in IART with the Ticky from Trade-Ideas. See the FREE profile for IART NOW at Trade-Ideas

More details on IART:

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. IART has a PE ratio of 525. Currently there are 7 analysts that rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Integra Lifesciences Holdings has been 331,800 shares per day over the past 30 days. Integra Lifesciences has a market cap of $2.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.70 and a short float of 13.2% with 9.80 days to cover. Shares are up 16.9% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Integra Lifesciences Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, increase in net income and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 5.7%. Since the same quarter one year prior, revenues rose by 16.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The gross profit margin for INTEGRA LIFESCIENCES HLDGS is currently very high, coming in at 72.40%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, IART's net profit margin of 4.91% significantly trails the industry average.
  • IART's debt-to-equity ratio of 0.94 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Regardless of the somewhat mixed results with the debt-to-equity ratio, the company's quick ratio of 1.46 is sturdy.
  • INTEGRA LIFESCIENCES HLDGS's earnings per share declined by 11.4% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, INTEGRA LIFESCIENCES HLDGS reported lower earnings of $0.20 versus $1.10 in the prior year. This year, the market expects an improvement in earnings ($3.44 versus $0.20).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Health Care Equipment & Supplies industry average, but is greater than that of the S&P 500. The net income increased by 38.9% when compared to the same quarter one year prior, rising from $8.38 million to $11.65 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.